Documents tabled in the Senate today raised serious questions about the information provided on PBAC deferrals at Senate Estimates. The advice to Mark Butler indicates the committee's chair may have been indirectly involved in formulating the plan, that the department is legally required to evaluate submissions lodged for March regardless of capacity constraints, and that officials did not consult the industry as directed.
Publication of ministerial advice raises questions about the evidence given at Senate Estimates
November 29, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News
